Insmed Earnings Yield: -64.60%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
INSM Earnings Yield Rankings
| Overall | 4th percentile | 4214 of 4402 |
| Sector | 8th percentile | 467 of 511 in Healthcare |
| Industry | 8th percentile | 147 of 161 in Biotechnology |
INSM Earnings Yield Range, Past 5 Years
| Minimum | -244.44% | Dec 2002 |
| Maximum | -9.76% | Dec 2003 |
| Average | -62.79% |
About Earnings Yield
Earnings yield is earnings per share from the previous four quarters divided by the share price. It is the reciprocal of the P/E ratio. The earnings yield is quoted as a percentage, which illustrates the percentage of each dollar invested that was earned by the company during the past twelve months.
The earnings yield can be used to compare the earnings of a stock, sector or the whole market against bond yields. Generally, the earnings yields of equities are higher than the yield of risk-free treasury bonds. Financial theorists argue that this difference exists because stock earnings are riskier than bond coupon payments.
If a company has an earnings yield of 64%, investors are purchasing $0.64 of earnings per dollar invested.
Learn More
You may also be interested in these INSM related companies
INSM News
Insmed (INSM) Commences ARIKACE Phase 2 in NTM Lung Disease Patients, Phase 3 in CF Patients w/ Pa
Feb 10, 8:05AM Street Insider
Feb 10, 8:05AM Street Insider
steppin out to meet tax man.....have order waitin on $INSM if it goes low enough
about 19 days ago by highgrowthfinancial
about 19 days ago by highgrowthfinancial
$INSM could of had 3k @$3.74, stubbornly left bid @$3.73...didn't fill 1 share.WTF! finished strong. will take another look tues
about 20 days ago by highgrowthfinancial
about 20 days ago by highgrowthfinancial
Unusual 11 Midday Movers 01/20: (INSM) (SCHS) (CPY) Higher; (NCIT) (CCOI) (THS) Lower
Jan 20, 1:43PM Street Insider
Jan 20, 1:43PM Street Insider
Feuerstein: Insmed Remove on Clinical Hold is "OK", But Still A lot of Overhanging Risk
Jan 20, 8:57AM Benzinga
Jan 20, 8:57AM Benzinga
FDA Lifts Clinical Hold on Insmed (INSM) ARIKACE in NTM Patients; Continues CF Negotiations
Jan 20, 8:03AM Street Insider
Jan 20, 8:03AM Street Insider
Insmed $INSM says FDA lifts clinical hold on arikace; shares currently halted for that news
about 23 days ago by Street_Insider
about 23 days ago by Street_Insider
Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Nov 14, 8:00AM PR Newswire
Nov 14, 8:00AM PR Newswire
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2011
Nov 08, 7:00AM PR Newswire
Nov 08, 7:00AM PR Newswire
$INSM so whats the point? same exact news took place and it dropped then went back above 3.50$
about 121 days ago by peoples
about 121 days ago by peoples
$INSM shares now down 15% pre-market as FDA continues clinical hold on Arikace trial
about 121 days ago by Street_Insider
about 121 days ago by Street_Insider
FDA Continues Clinical Hold on Insmed (INSM) ARIKACE Phase 3; More Info Needed
Oct 14, 8:10AM Street Insider
Oct 14, 8:10AM Street Insider
$INSM FDA Continuing Clinical Hold On Phase-3 Arikace Trial for Insmed
about 121 days ago by Benzinga
about 121 days ago by Benzinga
Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication
Oct 14, 8:00AM PR Newswire
Oct 14, 8:00AM PR Newswire
$INSM I already called the bottom @2.70 why this late report? http://stks.co/ZNW
about 124 days ago by peoples
about 124 days ago by peoples
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| INSM | 4.83 | -0.17 | -3.40% | 119.93M |
| PSMT | 72.03 | 0.83 | 1.17% | 2.15B |
| EBAY | 33.02 | -0.23 | -0.71% | 42.63B |
| DROOY | 6.15 | 0.02 | 0.33% | 236.71M |
| CTB | 15.93 | -0.62 | -3.75% | 991.80M |
| KMB | 71.56 | -0.32 | -0.45% | 28.20B |
| JNJ | 64.60 | -0.29 | -0.45% | 176.41B |
| XOM | 83.80 | -1.08 | -1.27% | 401.67B |
| APC | 87.04 | -0.42 | -0.48% | 43.34B |
| ADK | 4.50 | -0.09 | -1.96% | 44.59M |
